Sugi Predict

Sugi Predict / Compounds / SCHEMBL6917548

SCHEMBL6917548

SCHEMBL6917548

CNc1ccc(C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.67
▸ PTPN2 P17706 1/20 0.57
▸ PTPN1 P18031 1/20 0.57
▸ PTPN6 P29350 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.55
▸ MAPT P10636 2/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ GPR119 Q8TDV5 8/20 0.52
▸ DDB1 Q16531 1/20 0.52
▸ CRBN Q96SW2 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ IGF1R P08069 1/20 0.51
▸ JAK2 O60674 1/20 0.50
▸ JAK3 P52333 1/20 0.50
▸ PTK2 Q05397 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992672 0.92 NAMPT (0.58) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL1992669 0.92 NAMPT (0.58) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL21965379 0.88 NAMPT (0.66) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL20354696 0.88 NAMPT (0.66) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL7667693 0.87 NAMPT (0.69) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL10127488 0.87 NAMPT (0.71) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL6917648 0.86 NAMPT (0.52) NAMPTPTPN2PTPN1PTPN6ALDH1A1
Dimethylamine SCHEMBL6608623 0.85 NAMPT (0.65) NAMPTPTPN2PTPN1PTPN6MAPT
SCHEMBL18379198 0.85 GPR119 (0.62) NAMPTPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL3854559 0.85 NAMPT (0.61) NAMPTPTPN2PTPN1PTPN6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 — — EP disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 — — US disclosed
EP-3187490-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-07-05 — — EP disclosed
US-9452980-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2016-09-27 — — US disclosed
US-9452980-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2016-09-27 — — US disclosed
US-20160264596-A1 SUBSTITUTED BENZAMIDES HOFFMANN-LA ROCHE INC. 2016-09-15 — — US disclosed
US-20160264596-A1 SUBSTITUTED BENZAMIDES HOFFMANN-LA ROCHE INC. 2016-09-15 — — US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS NAMPT 4414/4885PTPN2 693/4885PTPN1 446/4885
US-20160264596-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885PTPN2 2000/4885PTPN1 2282/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 NAMPT 1700/4885PTPN2 693/4885PTPN1 789/4885
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885PTPN2 2000/4885PTPN1 2282/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 NAMPT 656/4885PTPN2 599/4885PTPN1 619/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885PTPN2 2000/4885PTPN1 2282/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B NAMPT 1889/4885PTPN2 569/4885PTPN1 675/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 NAMPT 4171/4885PTPN2 423/4885PTPN1 232/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R NAMPT 1606/4885PTPN2 2000/4885PTPN1 2282/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 NAMPT 1700/4885PTPN2 693/4885PTPN1 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.